Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASTRIC triplet therapy study in RAS-mutant metastatic colorectal cancer
NL-OMON60729Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of binimetinib, lapatinib and vinorelbine in colorectal cancer (CRC) and metastatic colon cancer (mCRC), sponsored by University Medical Center Utrecht. Primary endpoints: Dose-limiting toxicities and recommended phase II dose and Objective response rate. Started Jul 2020; status: completed.
02
Drugs
binimetiniblapatinibvinorelbine
03
Conditions
colorectal cancer (CRC)metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on NL-OMON60729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60729.